We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,271

Post-Grant Proceedings as a Freedom-To-Operate Tool
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • October 30 2017

While some may take it as a given that patent owners view America Invents Act post-grant proceedingsinter partes reviews and post-grant

How Companies Should Prep for Enforcement Shift to State AGs
  • Foley & Lardner LLP
  • USA
  • August 23 2017

“Top Cop” is how every state Attorney General wants to be known. In reality, state AGs have far more authority for civil enforcement than they do for

GlaxoSmithKline Consumer Healthcare (UK) IP Limited 2017 NZIPOTM 6 (2 March 2017)
  • Spruson & Ferguson
  • Australia
  • August 3 2017

This matter concerned a notice of intention to reject the following series of mark: The application is owned by GlaxoSmithKline Consumer Healthcare

SCOTUS Ruling Gives a Boost to Biosimilars; FDA Continues to Advance Products Through AdComs
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • June 14 2017

On a sweltering hot D.C. morning, those of us anxiously awaiting the Supreme Court’s opinion in its first case involving biosimilar biological

Liability as joint tortfeasor & the statute of limitation
  • Stobbs IP
  • United Kingdom
  • May 24 2017

Regular readers of our blog will already be familiar with the ongoing trade mark infringement and counterclaim battle between Glaxo and Sandoz, see

The SCA has initiated an investigation against Aspen Pharma for alleged excessive pricing
  • Callol, Coca & Asociados
  • European Union, United Kingdom
  • May 10 2017

On 3 February 2017, the SCA has initiated proceedings against Aspen Pharma Ireland Ltd, Aspen Pharmacare Holdings Limited and Aspen Pharma Trading

Food, Dietary Supplement & Cosmetics Regulatory Update Vol. IV, Issue 2
  • Jones Day
  • European Union, USA
  • March 17 2017

President Trump to Nominate Scott Gottlieb as FDA Commissioner According to a White House statement, President Trump

Section 3(d) of the Patents Act: interpretation continues to remain subjective
  • LexOrbis
  • India
  • March 15 2017

The government has recently taken several measures to strengthen the procedure of the IP offices and make them more transparent, including by

Texas Federal Court Rejects Attempt to Misapply Buckman to Invalidate Statutory Rebuttable Presumption of Warning Adequacy
  • Cozen O'Connor
  • USA
  • March 3 2017

We've addressed many times Texas Civil Practice & Remedies Code 82.007, a tort reform statute that, essentially, creates a presumption in drugs

AstraZeneca Chief Predicts Opportunities for Drug Makers After Brexit
  • Veale Wasbrough Vizards
  • European Union, United Kingdom
  • March 1 2017

There will be great opportunities for the UK life sciences sector after Brexit, according to Pascal Soriot, the Chief Executive of AstraZeneca (AZ